Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma

Authors: Gang Wu, Yawei Wang, Xiaojun Lu, Hui He, Haiyang Liu, Xiangyu Meng, Shuguan Xia, Kunming Zheng, Boqian Liu

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Recent studies have shown that miR-372 plays important roles in hepatocellular carcinoma (HCC) progression. However, results have been conflicting regarding its expression levels and role in HCC.

Methods

RT-PCR and in situ hybridization was used to evaluate miR-372 expression in HCC tissues and cell lines. The methylation status of neighboring CpG islands upstream of the miR-372 promoter was analyzed by methylation-specific PCR (MSP). Transfection of miR-372 mimic into HCC cell lines was used to evaluate cellular proliferation and invasion. Prognostic significance was analyzed by the Kaplan–Meier survival method and Cox regression.

Results

miR-372 was expressed at lower levels in HCC tissues compared with controls and was related to tumor metastasis and poor prognosis. Hypermethylation of miR-372 was detected in HCC cell lines and tissues, and miR-372 expression was restored upon 5-aza-dCyd treatment. Upregulated expression by mir-372 mimic transfection inhibited proliferation and invasion capacity in HCC cells.

Conclusions

miR-372 may play an important role in hepatic carcinogenesis and may serve as a new target or method to detect and treat HCC in the future.
Literature
1.
2.
Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH. Expression of FOXJ1 in hepatocellular carcinoma: Correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog. 2013;52(8):647–59.CrossRefPubMed
3.
He H, Wu G, Li W, Cao Y, Liu Y. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol. 2012;21:143–9.CrossRefPubMed
4.
Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–107.CrossRefPubMed
5.
Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene. 2006;25:3810–7.CrossRefPubMed
6.
Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, Aviel-Ronen S. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Bio. 2010;l42:1355–62.CrossRef
7.
Milazzo M, Fornari F, Gramantieri L. MicroRNA andhepatocellular carcinoma: biology and prognostic signicance. Minerva Gastroenterol Dietol. 2011;57:257–71.PubMed
8.
Li D, Liu X, Lin L, Hou J, Li N, Wang C, et al. MicroRNA-99a inhibits hepato-cellular carcinoma growth and correlates with prognosis ofpatients with hepatocellular carcinoma. J Biol Chem. 2011;286:36677–85.CrossRefPubMedPubMedCentral
9.
Voorhoeve PM, le Sage C, Schrier M, Gillis AJ. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124(6):1169–81.CrossRefPubMed
10.
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, et al. miR-372 regulates cellcycle and apoptosis of ags human gastric cancer cell line throughdirect regulation of LATS2. Mol Cells. 2009;28:521–7.CrossRefPubMed
11.
Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signaturepredicts survival and relapse in lung cancer. Cancer Cell. 2008;13:48–57.CrossRefPubMed
12.
Lai JH, She TF, Juang YM, Tsay YG, Huang AH, Yu SL, et al. Comparative proteomicproling of human lung adenocarcinoma cells (CL 1–0)express-ing miR-372. Electrophoresis. 2012;33:675–88.CrossRefPubMed
13.
Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;375:23–30.PubMed
14.
Wu G, Liu H, He H, Wang Y, Lu X, Yu Y, et al. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer. 2014;14:107. doi: 10.1186/1471-2407-14-107.CrossRefPubMedPubMedCentral
15.
Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32:1748–56.CrossRefPubMed
16.
Thomsen R, Solvsten CA, Linnet TE, Blechingberg J, Nielsen AL. Analysis of qPCR data by converting exponentially related Ct values into linearly related X0 values. J Bioinform Comput Biol. 2010;8:885–900.CrossRefPubMed
17.
18.
Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre` SA, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by Int J Oncol. 2014 Jul;45(1):35 targeting p27Kip1. J Biol Chem. 2007;282:23716–24.CrossRefPubMed
19.
Mertens-Talcott SU, Chintharlapalli S, Li X, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67:11001–11.CrossRefPubMed
20.
Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, et al. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med (Berl). 2009;87(1):43–51.CrossRef
21.
Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, et al. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer. 2010;10:109.CrossRefPubMedPubMedCentral
22.
Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX et. al. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis.,2011 Jul 22;286(29):25556–63. doi: 10.1074/jbc.M111.221564. Epub 2011 Jun 6.
23.
Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69:8491–8.CrossRefPubMed
24.
Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A. 2004;101:17216–21.CrossRefPubMedPubMedCentral
25.
Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients’survival. Hum Pathol. 2000;31:558–65.CrossRefPubMed
26.
Ihara A, Koizumi H, Hashizume R, Uchikoshi T. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology. 1996;23:1441–7.PubMed
27.
Wu G, Lu X, Wang Y, He H, Meng X, Xia S, et al. Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma. Int J Oncol. 2014;45(1):351–61.PubMed
28.
Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, et al. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology. 2012;82(4):205–12.PubMed
Metadata
Title
Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma
Authors
Gang Wu
Yawei Wang
Xiaojun Lu
Hui He
Haiyang Liu
Xiangyu Meng
Shuguan Xia
Kunming Zheng
Boqian Liu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1214-0

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Plasma membrane proteomic analysis of human Gastric Cancer tissues: revealing flotillin 1 as a marker for Gastric Cancer

Research article

Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study

Research article

Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors

Research article

STK33 overexpression in hypopharyngeal squamous cell carcinoma: possible role in tumorigenesis

Research article

Expression profiling of O6 methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases

Research article

Genomic profiling of CHEK2*1100delC-mutated breast carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits